Subsidiary’s Class 1 Innovative Chemical Drug HW221043 Tablets Approved for Clinical Trials
January 6, 2026
Source: drugdu
36
On January 5, ST Humanwell (600079) announced that its wholly-owned subsidiary, Hubei Bio-pharmaceutical Industrial Technology Research Institute Co., Ltd., has received approval to conduct clinical trials for HW221043 Tablets in patients with advanced solid tumors.
HW221043 Tablets are classified as a Class 1 chemical drug intended for the treatment of advanced solid tumors. As a New Molecular Entity (NME) independently developed by the company, there are currently no similar drugs approved for marketing either domestically or internationally. To date, the cumulative R&D investment for HW221043 Tablets totals approximately 24 million RMB.
In the first three quarters of 2025, ST Humanwell reported a revenue of 17.883 billion RMB and a net profit attributable to the parent company of 1.689 billion RMB.
https://finance.eastmoney.com/a/202601053608841348.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- “AI+RNA” Small Molecule Innovative Drug Approved for Clinical Trials January 8, 2026
- Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus January 8, 2026
- Amgen buys Dark Blue Therapeutics in $840m oncology deal January 8, 2026
- Kexing Biopharm’s licensed-in product, Albumin-bound Paclitaxel, has been approved for marketing by Argentina’s ANMAT January 8, 2026
- When animal testing is no longer a “must-have” option January 8, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
